Compare Invesco Ltd. (IVZ) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Novartis AG — how do they compare? Invesco Ltd. trades at $29.51 (market cap $13.28B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 20.2× Invesco Ltd.'s market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Invesco Ltd. for 77 Days and Novartis AG for 82 Days on average.
| IVZ | NVS | |
|---|---|---|
Market Cap | $13.28B | $268.57B |
Volume | 3,698,033 | 1,532,573 |
Sector | Financials | Health |
52-Week High | $33.31 | $168.62 |
52-Week Low | $22.44 | $121.80 |
Typical Hold Time | 77 Days | 82 Days |
Enterprise Value | $23.45B | $309.89B |
Dividend Yield | 2.86% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVZ trades at $30.09, down 1.34% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $281.70 million for 2025, though revenue grew to $6.38 billion. Analyst consensus is a $33.71 price target with no sell ratings, but technical indicators and recent negative profit margins highlight near-term challenges.
The outlook is cautious; while analyst support and a dividend provide some stability, persistent negative profitability and bearish technicals suggest limited upside until earnings improve. Key risks include execution on turning profits positive and market-sensitive revenue streams.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
